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Aptamers are single-stranded RNA or DNA molecules that specifically recognize their targets 
and have proven valuable for functionalizing sensitive biosensors. α-thrombin is a trypsin‐like 
serine proteinase which plays a crucial role in haemostasis and thrombosis. An abnormal activity 
or overexpression of this protein is associated with a variety of diseases. A great deal of attention 
was devoted to the construction of high-throughput biosensors for accurately detect thrombin for 
the early diagnosis and treatment of related diseases. Herein, we propose a new approach to 
modulate the interaction between α-thrombin and the aptamer TBA15. To this end, TBA15 was 
chemically conjugated to two peptide sequences (TBA-G3FIE-Ac and TBA-G3EIF-Ac) 
corresponding to a short fragment of the acidic region of the human factor V, which is known to 
interact directly with exosite I. Surface Plasmon Resonance (SPR) results showed enhanced 
analytical performances of thrombin with TBA-G3EIF-Ac than with TBA wild-type, reaching a 
limit of detection as low as 44.9 pM. Electrophoresis mobility shift assay (EMSA) corroborated 
the SPR results. Molecular dynamics (MD) simulations support experimental evidences and 
provided further insight into thrombin/TBA-peptide interaction. Our findings demonstrate that 
the combination of TBA15 with key interacting peptides offers good opportunities to produce 
sensitive devices for thrombin detection and potential candidates to block thrombin activity. 
 










α-thrombin is a trypsin‐like serine proteinase that plays a crucial role in haemostasis and 
thrombosis [1]. Since its discovery in the 19th century, α-thrombin has been extensively studied 
due to its complexity in function and regulation, since it acts paradoxically as pro-coagulant and 
as anti-coagulant factor [2]. α-thrombin is the product of an enzymatic amplification network, in 
which inactive components are activated by proteolyic cleavage [3-5]. A primary function of α-
thrombin relies on the conversion of soluble fibrinogen into insoluble fibrin clot [6], that anchors 
platelets to the site of an injury initiating the repair process [7].  
α-thrombin is composed by two polypeptide chains, chain A (36 residues) and chain B (259 
residues), which are covalently linked through a disulf de bond. Chain B is organized in two 
adjacent β-barrels and contains the active site and two basic exosites, I and II [4]. The active site, 
with the reactive Ser195 residue at the base, is highly negatively charged and located in a deep 
canyon flanked by two loops, the 60-insertion and ℽ-loop. These two loops restrict the entrance 
to the active site helping to establish the substrate and inhibitors specificity. The exosite I is 
located to the right of the active site and is also kn wn as fibrinogen recognition site. It contains 
hydrophobic patches and numerous charged residues. The location of these residues in the 
surface of exosite I provide electrostatics map-reading for the fibrinogen to the active site [8]. 
Exosite II is located opposite to exosite I and contains several charged residues, however does 
not include a hydrophobic area in the surface. Exosite II is prepared for the interaction with 
polyanionic ligands like glycosaminoglycan (GAG) and heparin [9, 10]. The natural substrates, 
cofactors and inhibitors compete for the three different sites of thrombin: the active site, exosite I 




For these reasons, α-thrombin is an important protein target for anticoagulation and 
cardiovascular diseases therapy [3, 5]. Endogenous α-thrombin inhibitors are serpins AT and 
HCII, however they need specific interactions with glycosaminoglycans, like heparin, to become 
efficiently active [3, 10, 13]. Heparin in its full or truncated low molecular weight forms has 
been selected as the most relevant anti-coagulant drug for the prevention and treatment of 
thrombosis [14]. In addition, heparin binds to a large number of regulatory proteins within the 
complement system [15] and to different blood cells, for instance endothelial cells and 
monocytes [16]. Exogenous inhibitors come from diverse protein families and are normally 
found in the saliva of blood suckers as part of an anticoagulant mix that allows them to feed [17, 
18]. 
In addition, single-stranded DNA oligonucleotides (s DNA) that bind specific thrombin [19, 
20] have been developed by selection of combinatorial libraries of oligonucleotides (SELEX) 
[21]. These ssDNAs molecules contained a 14–17 nt co sensus sequence, with eight highly 
conserved guanine residues, which form a central core built of two guanine quartets. These 
oligonucleotides are known as α-thrombin binding aptamers (TBAs). Among the TBAs, the 15-
mer with d(5′GGTTGGTGTGGTTGG3′)[19] sequence presents a strong anticoagulant activity 
at the nanomolar range [22]. Its interaction with the exosite I prevents α-thrombin to interact 
with fibrinogen and platelet aggregation [23, 24]. According to structural studies [25-27], TBA15, 
in the presence of α-thrombin or specific cations such as K+ forms an unimolecular, antiparallel 
G-quadruplex with a chair-like conformation, consisting of two G-quartets connected by a single 
TGT loop and two TT loops.  
Clinical trials have shown that this compound has interesting anticoagulant properties, 




have been studied in order to increase the affinity to thrombin and/or its stability to nuclease 
degradation [12, 28]. In addition a modest antiproliferative activity has been found for TBA as a 
consequence of potential binding to nucleolin [29]. Recently, modified TBA derivatives with 
higher antiproliferative activity and lower anticoagulant properties have been described [30, 31]. 
In addition, TBA has been used for the construction of biosensors for the detection of 
thrombin [32] and it has been used as model compound for the optimization of aptasensors [33]. 
New approaches for the design of pharmaceutical agents against thrombin could possibly take 
into account the synergistic effect of polyvalent binder’s. Herein, we design, synthesize and 
characterize for the first time the affinity of two α-thrombin binding aptamer conjugates that are 
covalently linked to a short peptide sequence corresponding to a fragment of the acidic region of 
the human factor V, which interact directly with α-thrombin exosite I [34]. This conjugation is 
expected to contribute positively to α-thrombin anchorage since both TBA and peptide have the 
ability to specifically bind to exosite I. Previous to this work oligonucleotides-peptide conjugates 
have been used as fluorescent probes, molecular tags [35] and cellular uptake enhancers [35, 36]. 
In particularly, a TBA-peptide conjugate was described for the visualization of K+ ions in cells 
[37]. But this peptide was mainly used as scaffold for anchoring a biotine and a fluorescent probe 
to TBA. In our communication, the peptide is designed to interact with thrombin providing a 
synergetic anchoring of the aptamer. For inspecting the effect of TBA-peptide conjugation on 
binding affinity, experimental techniques such as Electrophoresis Mobility Shift Assay (EMSA) 
and Surface Plasmon Resonance (SPR) will be conducte . This latter methodology will allow us 
to follow in real-time the binding of thrombin on the TBA-peptide functionalized biosensor, 
while determining accurately the limit of detection for α-thrombin. In turn, EMSA assay permits 




Molecular dynamics (MD) will be used to determine the free energies of binding between α-
thrombin and TBA-peptide conjugates. Information about the intermolecular interactions in the 




2.1. Design of the TBA-peptide conjugates 
The two crystals structures 1HAO [38] and the 3P6Z [34] containing α-thrombin bound to TBA 
or to the peptide (EIFEPPES) were used for the design of the conjugates. First, we selected just 
one of the two dimers described in the crystal structure 3P6Z. Then, the two α-thrombin 
molecules were superimposed using the molecular visualizer PyMOL. We extracted the TBA 
and the peptide coordinates to build up the connectivity between both molecules with the 
program Avogadro [39, 40]. Finally, the new coordinates were confirmed to verify whether 
TBA-peptide conjugates were located in exosite I. 
 
2.2. Synthesis of modified TBAs 
Modified TBAs were synthesized on several batches of 1-µmol scale (CPG) synthesis and the 
standard protocols [41]. The name and sequence of different modified TBAs are listed in Table 
1. The Amino-Modifier C6 was site-specifically inserted into the TBA at the5’ end. During the 
addition of the amino linker we avoided the use of the capping step to prevent partial acetylation 
of the amino group in further chemical steps. Oligonucleotides for biosensing were prepared 
starting with the 3’ end thiol modification and followed by 5’ additional thymidines. The solid 




2.3. Synthesis of TBA-peptide conjugate 
Solid-phase peptide synthesis was performed manually in a batch procedure using Nα-Fmoc-
protected amino acids. Syntheses were performed on 0.5-1μmol scale. First, the support carrying 
the 5’-amino oligonucleotides were treated with a solution of 20% piperidine in DMF for 4 min 
to remove potentially reactive acetyl groups[42]. Next, the MMT group was removed using 3% 
TCA in DCM, neutralized with 5% DIPEA in DCM and washed in CH3CN. The resulting 
support was treated with a mixture of Fmoc-amino acid (20 equiv), PyBOP (20 equiv) and 
DIPEA (40 equiv) in 0.2-0.3 ml of DMF for 5 hrs. Then, the solution was filtered and the support 
was washed with DMF and a second coupling of the same mino acid in the same conditions 
[Fmoc-amino acid (20 equiv), PyBOP (20 equiv) and DIPEA (40 equiv) in 0.2-0.3 ml of DMF] 
was performed over night. The glutamic acid couplings were performed with 20 equivalents of 
HATU instead of PyBOP. Next the resin was washed with CH3CN three times and twice with 
DMF. The Fmoc group was then removed using a 20% piperidine solution in DMF for 5 min and 
the support was washed in CH3CN and DMF. This process was repeated a second time. At the 
end of the synthesis the amino terminal was acetylat d with a mixture of Ac2O:DIPEA:DMF 
(0.1:0.17:1.53) to prevent the cyclation of the side chain of the glutamic acid.  
 
2.4. Deprotection and purification of TBA-peptide conjugate 
The side chain of the glutamic acid was deprotected with a 5% TCA solution in DCM for 1 hr, 
washed with CH3CN and dried. Next the supports were treated with 32% aqueous ammonia at 55 
°C for 1 hr or at room temperature overnight. Ammonia solutions were concentrated to dryness 
and the products were desalted over a NAP-10 column eluted with water. The resulting products 




flow rate 3 mL/min; solution A was 5% ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 
M aqueous TEAA. The length and homogeneity of the oligonucleotide-peptide conjugates were 
checked by MALDI-TOF (Table 1). The products concentration was determined by absorbance 
measurements (260 nm) and their extinction coefficint was considered as the TBA15. These 
samples were kept dry at -20 °C until further use. 
 
2.5. Melting Temperature studies and CD spectra 
Melting curves of the TBA-peptide conjugates were masured by monitoring the absorbance 
hyperchromicity at 295 nm. The UV absorption spectra were recorded at 1°C/min intervals, with 
a 1 min equilibration time at each temperature value; the sample was heated over the range 20-80 
ºC. Buffer solution was 10 mM sodium cacodylate pH 7.0 and 100 mM KCl. The concentration 
of the samples was around 1.66 μM. Each sample was allowed to equilibrate at the initial 
temperature for 5 min before the melting experiment was started. The melting temperatures (Tm) 
are the average value of a pair of Tm experiments. 
Circular dichroism (CD) measurements were recorded at the same concentration and using the 
same buffer as for the denaturing curves. The spectra were registered at 15 °C over a range of 
205–320 nm with a scanning speed of 100 nm/min, a response time of 4 s, a 0.5-nm data pitch, 
and a 1-nm bandwidth. 
 
2.6. α-thrombin-binding assay 
The interaction between TBA-peptide conjugates and α-thrombin were analyzed by gel 
electrophoresis. The TBAs-peptide conjugates (4 µM) were mixed with increasing 




100 mM Tris pH 7.4, 50 mM AcOH, 2 mM KCl, 12.5 mM Mg(OAc)2 and 5 mM EDTA. 
Complexes formation was analyzed on a 10% polyacrylmide gel at 80V, at 4 °C for 4 hrs in the 
same buffer.  
 
2.7. SPR analysis of the TBA-peptide conjugates with α-thrombin 
The interaction between α-thrombin and TBA-peptide conjugates was monitored an quantified 
by a home-made SPR [43]. Gold sensor chips were cleaned and prepared prior to experiments. 
Briefly, the gold chips were rinsed with pre heated solvents (i.e., trichloroethylene, acetone, 
ethanol, and dH2O). Then, sensor chips were dried with N2 flux and placed in a UV/O3 generator 
(BioForce Nanosciences, USA) for 20 min. After that, gold sensor chips were subsequently 
rinsed with ethanol and water and dried under N2 flux. The TBA peptide conjugates were 
immobilized with 100 mL of immobilization solutions (1 μM TBA-peptide in the following 
solution (20 mM Tris pH 7.4, 140 mM NaCl, 5 mM KCl, 1 mM MgCl2) in the gold chips in a 
humid chamber O/N. Then, they were rinsed with DEPC-H2O, dried with N2, and placed in the 
sensor device. The interaction between oligonucleotid -peptide conjugates and α-thrombin was 
detected by flowing over the sensor different concentrations of α-thrombin in the same buffer 
conditions at a 16 μL/min constant rate and at room temperature (RT). Finally, the data were 
collected using Origin 8.0 software. The experimental detection limit (LOD) was defined as the 
target concentration giving a ΔR (%) in the hybridization signal at least three times higher than 
that of the standard deviation of a blank signal. The limit of quantification (LOQ) was defined as 
the target concentration giving a ΔR (%) in the hybridization signal at least ten times higher than 





2.8. MD simulations 
2.8.1. Construction of solvated systems 
Molecular dynamics (MD) simulations were performed to study the binding energies of human 
α-thrombin with TBA15 and peptide-modified TBA. We sought to understand the effect of 
conjugating the newly designed peptides to TBA on α-thrombin/TBA interaction by comparing 
the average binding energies obtained from a set of replicate simulations. Similarly to what 
consider in peptide design, the crystal structures obtained from RCSB PDB with IDs 1HAO [38] 
and 3P6Z [34] were used to define the initial coordinates for the complexes α-thrombin/TBA 
(system 1), α-thrombin/TBA-G3FIE and α-thrombin/TBA-G3EIF. The Leap module of 
AMBER14 was used to modify the sequence of the reference peptide detailed in PDB 3P6Z to 
match the ones tested experimentally. The aminohexyl linker was parameterized in the R.E.D.D. 
server [44] that automates the calculation of RESP charges at the HF/6-31G(d) level of theory, 
consistent with AMBER’s ff14SB force field [45]. The lacking residues of human α-thrombin 
were modelled through the structural template-based tom fill-in tool Modeller9v15 [46]. The α-
thrombin extremes were capped with neutral acetyl and N-methyl group, respectively. The 
overall charge of α-thrombin was set to correspond to pH=7.4. The initial conformations were 
minimized for 2500 cycles applying the steepest-descent algorithm in implicit Generalized Born 
(GB) solvent. The resulting geometries were then solvated using a TIP3P waters [47] in an 
octahedral water box with a 12 Å padding in all directions around the surface of complexes. The 
solvent molecules added were made to be identical within systems, to ensure their accurate 
energetic comparison. The sodium and chloride ions were added to the systems to reach a 





2.8.2. Molecular Dynamics simulations 
Eight 50-ns MD simulations for each system were performed using AMBER’s ff14SB force 
field. Replicate simulations were assigned with different initial velocities, to generate 
independent simulations. Hydrogen bonds were held fixed using the SHAKE algorithm [48] 
Short-range interactions were set to a cutoff of 10 Å and particle mesh Ewald (PME) [49] was 
applied for long-range electrostatics. Minimization, heating and equilibration stages were 
sequentially performed involving: (i) 1000 steps for the steepest-descent algorithm, followed by 
1000 steps of conjugate-gradient algorithm, while 25 kcal mol-1 Å-2 of positional restraints were 
imposed on α-thrombin/aptamers atoms; (ii) 2500 steps of both algorithms, steepest-descent and 
conjugate-gradient were applied to unrestrained system ; (iii) systems were heated from 0 to 298 
K using Langevin thermostat over 1 ns with collision frequency of 2 ps-1 and 5 kcal mol-1 Å-2 of 
positional restraints on thrombin/aptamers atoms; (iv) finally, systems were equilibrated at 
constant pressure and at 300 K for 2 ns using Langevi  thermostat, and assigning 0.5 kcal mol-1 
Å-2 of positional restraints thrombin/aptamers atoms. For all stages the time step was set to 2 fs. 
MD runs were performed on Navigator computing cluster of LCA-UC [50] using the CPU 
version of PMEMD program in AMBER14 [51]. H-bond analysis were carried out in AMBER’s 
Ptraj program and processed via an in-house script developed by the authors using Fortran 77 
and R programming. The MD run that presented a value of free energy closer to the averaged 
free energy value was selected to conduct H-bond analyses. The distance between acceptor-
donor was considered to be equal or less than 3.5 Å and the angle cut-off of equal or higher than 
135°. The details of MM-GBSA analyses and the description of the method used for inspection 





3. Results and discussion 
3.1. Design of the TBA-peptide conjugates 
As starting point we analyzed two crystal structures of α-thrombin forming complex with TBA 
and a peptide derived from the human factor V from the RCSB protein data bank (PDB IDs 
1HAO [38] and 3P6Z [34]). The pdb 1HAO is the strucure of the complex between α-thrombin 
and TBA and the pdb 3P6Z contains a dimer of α-thrombin bound to the peptide with sequence 
EIFEPPES. After superimposing the two α-thrombin structures the binding region (exosite I) of 
the two ligands do not undergo significant conformational changes as a low RMSD value of 
0.481 was obtained (Supplementary Fig. 1). The peptide residues, EPPES, were removed to 
avoid overlapping with TBA nucleotides, while the coordinates of the last residues EIF were 
preserved. Upon analyzing the binding site of the TBA and the peptide we could observe a close 
proximity between the 5’ end of the TBA. Three glycine residues and a linker, aminohexyl, were 
introduced in peptide structure to allow the binding between 5’ end of TBA and peptide. The 
effect of the amino-acid sequence in the interaction o thrombin was inspected by constructing 
peptides with inverted sequences EIF and FIE. 
 
3.2. Synthesis, deprotection and purification of modified TBAs 
We synthesized the TBA–peptide using standard DNA synthesis [41] and Fmoc-protected amino 
acids using a method developed in our laboratory [42]. Usually, the stepwise synthesis of 
oligonucleotide-peptide conjugates using the same support starts with the assembly of the 
peptide, as Boc-protected amino acids can be employed avoiding the use of acid treatment in the 
presence of the oligonucleotide chains. However, in this case, the peptide moiety is located at the 




controlled pore glass (CPG) supports using standard 2-cyanoethyl phosphoramidites. After the 
completion of the TBA sequence, the N-6-MMT-aminohexyl-linker was incorporated to the 5’ 
end of the DNA to generate an amino group for the assembly of the peptide. Following the 
coupling of the amino linker, the capping step was avoided to prevent undesired acetylation of 
the amino group as described [42]. Nevertheless, a washing step with piperidine was 
incorporated prior to the deprotection of the aminohexyl-linker to remove potentially reactive 
acetyl groups that may be produced in  previous phos ramidite coupling cycles [42].  
Subsequently, the peptide sequences were assembled to the 5’ end of the TBA to obtain the 
desired oligonucleotides conjugate. For the addition of the triglycine sequence we used the 
available Fmoc-triglycine derivative. To increase th incorporation efficiency of glutamic acid, 
the coupling reagent PyBOP was replaced by HATU. The 2-phenylisopropyl (PheiPr) group was 
selected for the protection of the side chain of glutamic acid. Other acid labile groups such as t-
butyl ester were not adequate as the strong acid con iti ns needed for their removal can cause 
the depurination of the TBA oligonucleotide during the peptide deprotection step. In addition, we 
decided to acetylate the amino terminal end of the oligonucleotide-peptide conjugates before acid 
deprotection of the side chain of the glutamic acid in order to inhibit potential pyroglutamic 
formation and to increase the stability of the final product. The deprotection of the side chain of 
the glutamic acid was optimized by increasing the trichloroacetic acid solution percentage and 
the reaction time (5% and 1 hr). Finally, the treatment of the support with concentrated aqueous 
ammonia solution was used to deprotect the oligonucleotide moiety and liberate the conjugate 
from the solid support. The synthetic protocol is shown in scheme 1. 
The resulting synthesis crudes were analyzed by HPLC giving a main product. These products 




shown in Table 1. The HPLC profiles of the products obtained are shown in Fig. 1 and 
Supplementary Fig. 2. 
 
Scheme 1. Schematic representation of the process used in this work for the Solid-Phase 
Synthesis of Oligonucleotide-peptide conjugates including some small modifications to the 









Table 1. Sequence, melting temperature (Tm) and mass spectra of TBA-peptide conjugates 
prepared in this study.  
 




 ∆Tm Mcalc Mfound 
TBA GGTTGGTGTGGTTGG 49.5 - 4725/4726 
TBA-Ac GGTTGGTGTGGTTGG-linker-Ac 40.2 -9.3 4946/4950 
TBA-G3FI GGTTGGTGTGGTTGG-linker-G3FI 40.8 -8.7 5377/5372 
TBA-G3EIF-Ac GGTTGGTGTGGTTGG-linker-G3EIF-Ac 35.1 -14.4 5506/5511 
TBA-G3FIE-Ac GGTTGGTGTGGTTGG-linker-G3FIE-Ac 39.1 -10.5 5506/5502 
b
R-S-S-T5-TBA-G3EIF-Ac 
5           3 
R-S-S-TTTTTGGTTGGTGTGGTTGG-linker-G3EIF-Ac n.d. ---- 7273/7282 
b
R-S-S-T5-TBA-G3FIE-Ac 
5           3 
R-S-S-TTTTTGGTTGGTGTGGTTGG-linker-G3FIE-Ac n.d. ---- 7273/7277 
 
 
a 10 mM sodium cacodylate, 100 mM KCl pH 7.  
b disulfide protected form. Uncertainty 0.5°C. n.d. not determined. Linker: O-phosphate-O-(CH2)6-NH.  
 
3.3. Thermal denaturation studies and CD spectra 
In order to analyze the effect of the incorporation of short peptide sequence at the 5’ end of the 
TBA in the stability of the intramolecular antiparallel quadruplex structure, we have recorded the 
corresponding melting curves (Supplementary Fig. 3) allowing us to determine the melting 
temperatures (Tm), (see Table 1). A single transition was observed at 295 nm that corresponds 
to the denaturation of G-quadruplexes [52]. 
Unmodified TBA presents a Tm of 49.5 C and shows a CD spectrum with positive peaks at 
295 and 245 nm as well as a negative peak at 265 nm. These features are in good agreement with 
those reported previously for antiparallel G-quadruplex [53, 54]. Surprisingly, the incorporation 
of the acetylated amino linker at the 5’ end of the TBA produced a considerable decrease in the 
thermal stability of the TBA obtaining a Tm of 40.2 °C and it may be due to the presence of the 
phosphate group at the 5’ end [55]. This reduction in thermal stability is maintained in one of the 
two peptide sequences and in its truncated version w thout the glutamic acid (TBA-G3FIE-Ac 




However, the oligonucleotide-peptide conjugate TBA-G3EIF-Ac presented a higher decrease 
in the stability of the quadruplex structure (∆Tm = -14.4 °C). The exchange of the two amino 
acids in the peptide sequence increase ∆T by ca. 4 °C. These results indicated that the 
incorporation of a phosphate group and a short peptid  sequence at the 5’ end has an influence in 
the stability of the G-quadruplex structure, which depends on the position of each amino acid in 
the sequence. Nevertheless, the CD spectra of the two modified TBA-peptides presented the 
typical features of an antiparallel G-quadruplex as TBA alone, indicating that the incorporation 
of the peptide sequence at the 5’ end does not affect th  overall structure as it is shown in Fig. 2. 
 
Fig. 2. CD spectra of the two oligonucleotide-peptide conjugates synthesized at 15 ºC compared 





3.4. α-thrombin-binding assay by EMSA 
Next, we studied the complex formation between α-thrombin and the TBA-peptide conjugates 
(see Table 1 for sequences) by electrophoresis mobility shift assay (EMSA). The amounts of 
TBA-complex formed at several TBA:Thrombin molar ratios are shown in Fig. 3. At all TBA: 
Thrombin molar ratios, the highest amount of thrombin complex was observed for TBA-G3EIF-
Ac followed by unmodified TBA and finally TBA-G3FIE-Ac showed the lower affinity for α-
thrombin. From these results and contrary to what could be expected from the decrease in G-
quadruplex stability in the melting temperature experiments, we could conclude that the 
incorporation of a short peptide sequences at the end of the TBA does not disrupt its interaction 
with α-thrombin. These results are in agreement with others presented in the literature showing 
that α-thrombin binding is not dependent of the thermal st bility of TBA modifications [30, 56]. 
Also, these results indicated that the affinity of the TBA for α-thrombin can be increased and 
modulated by the incorporation of a peptide sequence i  the respective ends, and that the amino 





Fig. 3. EMSA assay of complexes between α-thrombin and TBA-peptide conjugates in 100 mM 
Tris pH 7.4, 50 mM AcOH, 2 mM KCl, 5 mM EDTA, 12.5 mM Mg(OAc)2. 
 
3.5. SPR analysis of the TBA-peptide conjugates with α-thrombin 
SPR technology has been used to analyze thrombin interaction with different types of ligands 
[57, 58]. To prevent possible steric obstruction of the active site and of the exosite I of the 
protein, we decided to immobilize in the gold surface the unmodified and modified TBAs. For 
that purpose, we used TBAs modified with a thiol-group at the 3’-end, which will allow their 
attachment to the gold surface by chemisorption through thiol-gold chemistry. We included, also, 




the G-quadruplex structure and the accessibility of α-thrombin [59]. CD spectra confirm the 
antiparallel G-quadruplex structure of the thiolated oligonucleotides although the CD maxima 
are less intense than the unmodified TBA (data not sh w). The binding event is observed by 
alterations of the optical properties of the gold surface. Tiny variations in the refractive index 
produced by the interaction between TBA and α-thrombin changed the intensity of the reflected 
light, allowing real-time monitoring of the capture. We have studied the interaction of two 
peptide-TBA conjugates (TBA-G3EIF-Ac and TBA-G3FIE-Ac) with α-thrombin. For 
comparison purposes, we also assayed the complex int raction between the unmodified TBA 
with α-thrombin. 
All results obtained with the three unmodified and modified TBA bioreceptors are show in 
Fig. 4 and Fig. S4. We evaluated the interaction of the peptide-TBA conjugates with a range of 
α-thrombin concentrations. Triplicate measurements ad calibration curves of each interaction 
were obtained and are represented in Fig. 4. The limits of detection (LOD) and quantification 
(LOQ) for each bioreceptor were calculated.  
When comparing the obtained SPR curves, results show a clear difference in the 
performances of the modified surfaces for the detection of the α-thrombin analyte. The surface 
Gold-S-T5-TBA-G3FIE-Ac showed the lowest affinity to interact with α-thrombin, having a limit 
of detection of 124.33 pM and R2=0.71 remarkably lower than the one calculated for TBA (49.12 
pM, R2=0.93). On the other hand, the biosensor with a surface functionalized with the Gold-S-
T5-TBA-G3EIF-Ac displays enhanced analytical performances for α-thrombin in comparison 
with the latter one, reaching a LOD of 44.9 pM with R2=0.99. As expected, the values calculated 
for the limit of quantification follow the same trend as LOD. The values obtained for LOD are in 




nanomolar discarding the SPR biosensors that enhance their sensitivity by means of 
amplification procedures or by exploiting the properties of nanoparticles [62]. 
The higher sensitivity detected for surfaces functionalized with Gold-S-T5-TBA-G3EIF-Ac 
corroborates the data obtained from electrophoresis experiments. From these experiments, it is 
clear that by conjugating a peptide moiety derived from human factor V with TBA, the affinity 
of the aptamer for thrombin can be modulated, revealing an useful approach to build better 
biosensors for thrombin detection.  
 
Fig. 4. SPR measurements of the TBA-peptide conjugates with α-thrombin. In panel A, 
schematic representation of the gold sensor chip functionalization with TBA as a receptor 
through a thiol-linker. In panel B, SPR curves of the detection of the interaction between α-
thrombin with TBA or with the two TBA-peptide conjugates variant in 20 mM Tris pH 7.4, 140 
mM NaCl, 5 mM KCl, 1 mM MgCl2. All data show mean value ±SD from the SPR-equilibrium 
signal of three measurements. In panel C are indicated the limits of detection (LOD) and the 




3.6. MD simulations 
MD simulations have proven valuable in determining the thermodynamic properties of 
protein/ligand complexes in atomic detail, endowing a powerful predictive complement to 
experiments [63, 64]. We sought to compare the binding affinities of the complexes tested 
experimentally whilst gaining further insight regarding the sources dominating in thrombin and 
modified TBAs interaction. As mentioned above, the crystal structures 1HAO and 3P6Z were 
used to establish the initial positions of protein, peptides and aptamer, and different start 
velocities were imposed on simulation replicates to enhance sampling. In all the simulation runs, 
complexes rapidly reached equilibrium and show low RMSD oscillations in the last nanoseconds 
of simulation (Supplementary Fig. 5). In comparison, the RMSD variance range of the TBA 
conjugated to peptides is wider than the one of wild-type, suggesting that the presence of peptide 
induces larger conformational changes upon binding. In addition, the RMSF plot displays similar 
atomic fluctuation patterns for the thrombin bound to TBA and thrombin bound to modified-
TBA which in general fluctuate < 1 Ǻ (Supplementary Fig. 6). An exception occurs only for the 
ℽ-loop displaying higher atomic fluctuation especially when having TBA-G3FIE-Ac. 
For determining the thermodynamic properties involved in the interaction of α-thrombin and 
the set of aptamers tested experimentally the binding free energies were assessed by MM-GBSA 
methodology. This methodology is a popular method t estimate absolute free energies of 
protein-ligand complexes with a moderate computation l effort [65, 66]. The average absolute 
binding free energy estimates are compared in Fig. 5A. The specific values for each replicate as 
well as the decomposed energies into the various items from electrostatics, Van der Waals, non-
polar solvation and electrostatic solvation interactions are listed in supplementary Table 1. By 




experimental observations. In particular, the conjugation of TBA with G3EIF-Ac clearly 
enhances the interaction of α-thrombin/TBA (∆Gbind= -26.1±3.9 kcal mol-1 for thrombin/TBA 
and ∆Gbind = -44.2±8.0 kcal mol-1 for thrombin/TBA-G3EIF-Ac) while the conjugation with the 
parent G3FIE-Ac peptide weaken the α-thrombin/TBA interaction (∆Gbind = -20.8±5.9 kcal mol-
1). The value of absolute binding free energies estimated for α-thrombin/TBA is larger than those 
reported experimentally, which are comprised between -8 and -10 kcal mol-1, calculated through 
different techniques [67-70]. It is well-known that the MM-GBSA method neglects the entropy 
loss associated with bound water molecules in a protein-ligand complex, but nevertheless this 
methodology provides a useful tool to compare related complex systems. The present results 
show that the trend found computationally is in good agreement with results obtained with 
EMSA and SPR assays.  
In general, the decomposition of the binding free en rgy into different energy items highlights 
the relevant contribution of nonpolar and hydrophobic interactions (∆Gnonpol = ∆Evdw + ∆GSA) to 
binding free energies. Despite being unfavorable, the electrostatic contribution is more 
pronounced in thrombin/TBA-G3EIF-Ac complex, since ∆Gpol become less positive. When 
binding free energies are decomposed into individual residues (see Fig. 5B), the results show 
differences between systems. For the wild-type TBA, the most contributive residues are the 
nucleotides located on the TT loops, 3, 4, 12 and 13 that are in close vicinity to α-thrombin 
exosite I. The conjugation of peptides to the TBA preserves the same profiles of interaction but 






Fig. 5. MM-GBSA binding energy results for the α-thrombin/TBA, α-thrombin/TBA-G3FIE-Ac 
and α-thrombin/TBA-G3EIF-Ac simulation sets. The absolute binding energy values obtained 
for the 8 independent simulations are distinguished by different colored symbols while the bar 
indicates the overall mean value. All the data are giv n in kcal mol-1, and the specific values for 
each replicate and average are provided in supporting information Table S1. Error bars 




Furthermore, the residues of G3FIE-Ac peptide present low affinity to the thrombin residues 
being the isoleucine (I) and phenylalanine (F) the most prominent for the binding (>1 kcal    mol-
1). For TBA-G3EIF-Ac the triad E, I and F, in this order, make significant contributions to the 
binding affinity. The hydrogen bond analysis, depicted in Fig. 6A, detected four stable H-bonds 
not discarding ionic bonds between the amide groups of Arg75 and Tyr76 and the carbonyl 
groups of dT14 and dT13, while other contacts are established with protein residue Arg77A and 
the TBA nucleotides dT13 and dT14, as detected alsoin crystal structure [54, 71, 72]. The 
conjugation of G3FIE-Ac peptide displays H-bonds with a dynamic occupancy, and just two 
prevalent H-bonds, where one is established between the glutamic acid (E) and Arg73 (Fig. 6B). 
In turn, TBA-G3EIF presents several long time H-bonds formed not oly between thrombin/TBA 
and thrombin/peptide but also within peptide/TBA (Fig. 6C). In this case, the peptide is buried in 
thrombin tertiary structure reaching inner residues such as Gln29 and Leu31, moving away from 





Fig. 6. Interaction between α-thrombin/TBA, α-thrombin/TBA-G3FIE-Ac and α-thrombin/TBA-
G3EIF-Ac. In the panels are represented the occupancies of the most prominent hydrogen bonds 
formed between α-thrombin and a) TBA15, b) TBA-G3FIE-Ac and c)TBA-G3EIF-Ac. Data 





In addition, for a detailed description of intermolecular interactions, the binding patterns 
within the ternary systems thrombin/TBA-peptide arenalyzed based on the topological features 
of the electronic charge densities, in order to decouple the types of interaction and rationalize the 
respective strengths. In Fig. 7 and 8 the volume of the interacting regions allows inferring on the 
extent of the interactions within the thrombin/TBA-peptide conjugates. Binding specificity is 
suggested by discrete regions of enhanced interactions represented by the 3D isosurfaces. This 
specificity depends, as expected, on the nature of the protein residues involved in the interaction. 
Blue and red denote, respectively, stronger stabilizing/destabilizing interactions, while green 
indicates weak van der Waals-type interactions. Also included, are the respective 2D scatter 
plots, in which the asymmetry of the peaks reflects the favourable nature of the protein/ligand 
interactions. The peaks on the negative, stabilizing side of the plot are more intense than the 
corresponding peaks on the positive, destabilizing side, indicating that the balance of 
noncovalent forces in each binding scenario are in overall favouring the complex formation and 
stability. 
A clear difference between both thrombin/TBA and thrombin/TBA-G3FIE-Ac and 
thrombin/TBA-G3EIF-Ac is observed in Fig. 7 (panels A and B) and (panel A and C) 
respectively. The stability of the former interactions is essentially governed by several N-H⋯O 
hydrogen-bonds (represented by large volumes with blue centers), as also observed in Fig. 6. 
These hydrogen-bonds are identified by large diffuse peaks (ca. 5 N-H⋯O hydrogen-bonds in 
thrombin/TBA and 5 N-H⋯O and 1 N-H⋯O hydrogen-bonds in thrombin/TBA-G3FIE-Ac), 
with the respective maximums defined at -0.05< sign(λ2)ρ <-0.02. In thrombin/TBA-G3EIF-Ac 
(panel c), the type of hydrogen-bonds is similar, although the double (N-H)2⋯O involving 





Fig. 7. Interaction patterns underlying the complexes betwe n α-thrombin and (A) TBA, (B) 
TBA-G3FIE-Ac, and (C) TBA-G3EIF-Ac, represented in the 2D scatter plots (left) and IGMPlot 
isosurfaces (right). The structures of the complexes correspond to the last snapshot of 50 ns MD 
simulation. Isosurfaces show the total IGM interaction points for δginter ≤ 0.1 and in the region 
−0.2 ≤ sign(λ2)ρ ≤ 0.2. and are colored based on a blue-green-red scheme over the electron 
density range -0.04 < sign(λ2)ρ < 0.04 a.u. Stabilizing/destabilizing noncovalent interactions are 
thus represented in blue/red and van der Waals forces are colored in green. Thrombin side 
chains are represented in white as cartoon while some relevant amino acids are featured in ball-





These stronger hydrogen bonds are identified as the larg r diffuse peaks at sign(λ2)ρ ≈ -0.054 
and sign(λ2)ρ ≈ -0.05, respectively, in the corresponding 2D scatter plot. There is also a third 
well-defined peak corresponding to the ARG77A(N-H)-DT4(O). In addition to the N-H⋯O 
hydrogen-bonds derived from the ARG75(N-H)-DT4(O) and also ARG774(N-H)-DT4(O) the 
thrombin-TBA-G3EIF binding is also stabilized by slightly enhanced van der Waals interactions 
(corresponding to the flat green regions), established between ARG75 and DG5, ARG77A and 
DT13 and TYR76 and DT3-DT4 rings. In contrast to thrombin/TBA (panel A) and 
thrombin/TBA-G3FIE-Ac (panel B), these weakly stabilizing van der Waals-type interactions are 
represented by the solid peak at sign(λ2)ρ ≈ -0.02. Such weak attractive forces have been 
recognized as important driving forces in the binding process of similar systems involving 
proteins and aptamers [38]. 
From Fig. 8 (panels A and B), it is observed that the van der Waals interactions are almost 
comparable when the binding of protein/peptide-G3EIF-Ac and protein/peptide-G3FIE-Ac are 
considered. However, the number and nature of the hydrogen-bonds differ. In protein/peptide-
G3FIE-Ac (panel A) two N-H⋯O hydrogen bonds are established between ARG77A(N-H) and 
the carboxylic group of glutamic acid. The latter is also involved in one O-H⋯O hydrogen bond 
with the SER162 (O-H) moiety. These interactions can be identified in the more intense peaks on 
the left, at sign(λ2)ρ ≈ −0.05 and sign(λ2)ρ ≈ −0.03, respectively. The protein/peptide-G3EIF-Ac 
binding (panel B) is favoured by four N-H⋯O hydrogen bonds established between LEU31(N-
H)-ACE(O), I(N-H)-GLN29(O), and two ARG75(N-H)-E(O) and TYR86(N-H)-E(O). The triad 
ACE, F and I establish a network of stabilizing van der Waals interactions with neighbour 
protein residues. This extensive number of attractive interactions between G3EIF-Ac and 




interactions promoted by both peptides, we may hypothesize that G3FIE-Ac competes with TBA 
to interact with thrombin’s exosite I, while G3EIF-Ac shows the ability to interact with residues 
present in a distant region from exosite I, thus providing an additional interaction site, without 
disturbing the interaction between thrombin/TBA. Other peptides have demonstrated high 
affinity of phenylalanine to thrombin residues located in regions comprised within 31-35 
residues [73, 74], providing useful insights for the design of high-affinity peptides. 
 
Fig. 8. IGMPlot isosurfaces illustrating the existent i ermolecular interactions established 
between A) thrombin and G3FIE-Ac and B) thrombin and G3EIF-Ac. Stabilizing/destabilizing 
noncovalent interactions are represented in blue/red and van der Waals forces are colored in 
green (volume cutoff of δginter=0.15; color coding: −0.1 ≤ sign(λ2)ρ ≤ 0.1). α-thrombin side 
chains are represented in white as cartoon while some relevant amino acids are featured in ball-
and-stick, where carbon atoms are colored in grey, nitrogen in blue, oxygen in red and hydrogen 





Similarly to antibodies, DNA aptamers are widely used in biosensors and in the production of 
targeted therapies but offer several advantages includi g straightforward chemical synthesis, 
small size, lack of immunogenicity and possibility of chemical modification. Backbone and 
nucleobase modifications are the most commonly used strategies to increase nuclease resistance 
and/or to increase the affinity to the target [12]. In this work we described a new approach for the 
design of α-thrombin high-affinity conjugates, taking into account the synergistic effect that 
could arise from the combination of more than one bi der. As demonstrated both experimentally 
and computationally, the covalent binding of TBA with a short peptide sequence, derived from 
the acidic region of human factor V which interacts directly with the exosite I, increases the 
TBA’s affinity to the target α-thrombin protein. During the characterization, we have seen that 
this conjugate preserves the typical structural featur s of an antiparallel G-quadruplex, as the 
natural TBA. The free energies determined by MM-GBSA method reproduce the experimental 
evidences obtained in both EMSA and SPR methods. In particular, coupling the peptide G3EIF-
Ac guaranteed higher binding affinities than the cognate G3FIE-Ac or the TBA alone. An 
accurate evaluation of intermolecular interactions within the complex demonstrated that G3EIF-
Ac promote H-bonds with thrombin residues not located in exosite I and also exhibit interactions 
with TBA. On the other hand, the reverse G3FIE-Ac seems to compete with TBA for the same 
thrombin region. Therefore, the amino acid sequence se ms to be determinant for the 
reinforcement of thrombin/TBA-G3EIF-Ac interaction. The results described in the prsent work 
encourage the development of new oligonucleotide-peptid s conjugates with potential to increase 
the affinity to target α-thrombin. In addition, this strategy is compatible with existing backbone 
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Reagents, instrumentation, MM-GBSA analyses, analysis and visualization of noncovalent 
interactions, superposition of the two crystal structures (supplementary Figure. 1), HPLC 
analytical profiles (supplementary Figure. 2), Melting temperatures profile (supplementary 
Figure. 3), SPR raw data (supplementary Fig. 4), Structural variations for the three simulation 
systems obtained MD simulations (supplementary Figure. 5), Root-mean-square-fluctuation 
(RMSF) (supplementary Figure. 6). Binding free energy calculated by MM-GBSA methodology 
(supplementary Table 1). 
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1. Material and methods 
1.1. Reagents 
The standard ancillary reagents and phosphoramidites us d on the TBA synthesis were obtained 
from Applied Biosystems and Link Technologies Ltd. 5'-MMT-Amino-Modifier C6-CE-
phosphoramidite and 3'-Thiol-Modifier C3 S-S CPG were obtained from Link Technologies. 
Matrix for MALDI-TOF experiments was composed by 2’,4’,6’-trihydroxyacetophenone 
monohydrate (THAP, Aldrich) and ammonium citrate dibasic (Fluka). Solvents for HPLC 
analysis and purification were prepared using acetonitrile (Merck) and triethylammonium acetate 
(TEAA) as mobile phase. The Fmoc-glutamic acid and the Fmoc-Gly3 were purchased to 
Novabiochem and the rest of amino acids to Sigma. The rest of the chemicals are analytical 
reagent grade from commercial sources as specified. Solvents used for gold sensor chip cleaning 
were purchased from Panreac Applichem (Barcelona, Sp in): Acetone 99.5% and Ethanol 99%. 
Main salts and chemical reagents for all the experim nts, sensor cleaning, buffer preparation and 
biofunctionalization were acquired from Sigma-Aldrich (Germany): sodium dodecyl sulfate 
(SDS), hydrochloric acid (HCl), sodium hydroxide (NaOH), sodium chloride (NaCl) ≥99.5%, 
potassium chloride (KCl) and Magnesium chloride (MgCl2). 
1.2. Instrumentation 
Modified TBA sequence was synthesized on an ABI 3400 DNA Synthesizer (Applied 
Biosystems). Semipreparative and analytical RP-HPLC was performed on a Waters 
chromatography system using Nucleosil 120 C18 (250x8mm) and XBridge OST C18 
respectively. Mass spectra data were recorded on a MALDI Voyager DE RP time-of-flight 
(TOF) spectrometer (Applied Biosystems). Absorption spectra between 220 and 300 nm and the 
melting temperatures at 295 were recorded with a Jasco V650 spectrophotometer equipped with 
a Peltier temperature-controlling unit. The temperature was controlled with an 89090A Agilent 
Peltier device. Hellma quartz cuvettes were used. CD spectra were recorded on a JASCO 
spectropolarimeter J-810. Polyacrylamide gels were imaged with a Gene Genius Bioimaging 
system (Syngene). Model building was performed in Avogadro. The home made SPR [75] 
sensor platform is based on Kretschmann configuration, monitoring the binding interaction in 




focused on the crystal-backside of the sensor chip (glass surface coated with 2 nm of chromium 
and 45 nm of gold, 10×10×0.3 mm from SSens, Enschede – The Netherlands). The flow system 
consists of two flow cells (300 nL each) for two simultaneous and independent analysis. 
Measurements were performed at a fixed angle of incide e and the variations of the refractive 
index (RI) were detected in a multielement photodiode. The device incorporates all optics, 
electronics and fluidics components necessary to operate autonomously. Sensograms reproduce 
the binding event by monitoring the increase (or decrease in case of unbinding events) of the 
intensity of the reflected light (ΔReflectivity (%), ΔR (%)) vs. time (seconds, s). This change of 
the intensity of the reflected light is directly related to changes in the RI of the dielectric medium 
caused by mass changes on the metallic surface. Origin 8.0 software (OriginLab, Northampton, 
MA) is used to collect the data. 
2. MD simulations 
2.1. MM-GBSA analyses 
 
The end-state calculation Generalized Born and surface area continuum solvation (MM-GBSA) method 
[76] was used to obtain a detailed description of the α-thrombin/TBA interaction. Following this 
approach, the binding free energies were calculated according to:  
 
∆Gbind = [Gα-thrombin/15-TBA (X)] – [Gα-thrombin (X)] [G15-TBA (X)]     (1) 
 
in which the parameters are estimated from frames, denoted as (x), taken from the replicate MD 
trajectories. For each frame, the free energy of a state is estimated by: 
 
G(x) = Hgas (x) + Htrans/rot (x) + Gsolvation (x) – TS (x)      (2) 
 
Where Hgas (x) and Htrans/rot (x) are calculated from internal (bond, angle, dihe rals), electrostatic 
and van der Waals energies. The Gsolvation (x) includes the input of polar and non-polar terms in 
which the polar contribution is typically obtained by using the generalized Born (GB) model 
whereas the non-polar tern is estimated from the solvent-accessible surface area (SASA) 




conformational entropy to the binding. MM-GBSA analyses were made with MMPBSA.py 
program in AMBER14 using the last 1000 frames from the equilibrated trajectory with a single 
trajectory approach. For MM-GBSA, a level-set-based dielectric model was used with an ionic 
strength equal 150 mM, and a solvent probe of 1.4 Å radii. The average values for binding 
energy are calculated from the 8 independent simulations. SEM values were calculated by the 
value of sample standard deviation divided by the square root of the total number of simulations. 
 
2.2. Analysis and visualization of noncovalent interactions 
 
The noncovalent interactions within α-thrombin/TBA complexes are evaluated resorting to the 
Independent Gradient Method (IGM)3 and the IGMPlot software (version 1.0). These are 
specially useful for inspecting weak interactions i protein structures and related complexes [77-
79]. IGM is ruled by the topological characteristic of the electronic charge density, ρ, of each 
system. In addition to ρ, other relevant quantities related to the first and second derivatives of the 
density are considered. The IGM descriptor δginter is defined by the difference between the first 
derivatives of the charge densities for the total system and the fragments 
 
δginter = |ρIGM, inter | – |ρ|          (1) 
 
The presence of NCI is indicated by δginter>0 and the respective strength is reflected by the 
magnitude of the descriptor at a point in space.   2ρIGM, inter is calculated from sums over all the 
atomic densities in the different fragments denoted A and B in the x-direction, 
 
                                                                                 (2) 
 
IGMPlot uses the pre-computed atomic charge densitis for constructing a promolecular density 
producing a minimal effect on the NCI, as in these xtremely low-density regions a very little 
relaxation of the charge density occurs, following the formation of covalent bonds. Also, a 
discrimination between favorable and unfavorable NCI is dependent on the second derivative 
(Laplacian) of the density  2ρ, which can be decomposed into three eigenvalues of maximal 
variation,  2ρ = λ1 + λ2 + λ3 (λ1 ≤ λ2 ≤ λ3) providing information on the stabilizing (λ2< 0) or 




interactions, such as hydrogen bonds, while sign(λ2)ρ values close to zero are associated to weak 
NCI including van der Waals forces. Specifically, the coordinates of the each complex were 
extracted from last frame of the simulations that presents a free energy value closest to the free 
energy mean value. Solvent molecules were removed and the complexes were dissociated into 
the respective binding components (thrombin/TBA, thrombin/peptide, peptide/TBA). NCI are 
represented in space by isosurface volumes for the δginter colored according to the values of 
sign(λ2)ρ at each point on the surface. This allows inferring on the (de)stabilizing nature and 
extent of the interactions. The preparation and representation of the systems and isosurface 
graphics were carried out using the Visual Molecular Dynamics software version 1.9.2. [80] A 
quantitative evaluation of the types and strengths of NCI within the complexes was assured by 






Supplementary Figure 1. Superposition of the two crystal structures of human α-thrombin 
bound to the TBA (PDB ID: 1HAO) and to the peptide (EIFEPPES) ((PDB ID: 3PZ6). α-
thrombin are colored in yellow and blue, TBA in orange and the peptide sequence in dark blue. 
α-thrombin structures are represented by the secondary structure elements (new ribbons 





Supplementary Figure S2. HPLC analytical profiles of the different product obtained conjugate 





Supplementary Figure 3. Melting temperatures profile of the different oligonucleotide-peptide 
conjugates. The samples were in 10 mM sodium cacodylate pH 7.0 and 100 mM KCl and were 





Supplementary Figure 4. SPR raw data of the experiments shows the interaction between α-
thrombin and TBA-peptide conjugates variant. 1 μM TBA-peptide in the following solution (20 
mM Tris pH 7.4, 140 mM NaCl, 5 mM KCl, 1 mM MgCl2) was immobilized and different 
concentrations (from 0.01 to 1 µM) of α-thrombin were flowed in, using the same buffer at a 16 





















Supplementary 5. Structural variations for the (A) α-thrombin/TBA, (B) α-thrombin/TBA-
G3FIE-Ac and (C) α-thrombin/TBA-G3EIF-Ac simulation systems obtained MD simulations. 
The structural behavior of α-thrombin and the three aptamers is shown separately. The heavy 




selected for carry out the root-mean-square-deviation (RMSD) analyses, taking the first frame of 
the production run as the RMSD reference. The RMSD values for the eight replicates are 
compiled in each graph. 
 
Supplementary Figure 6. Root-mean-square-fluctuation (RMSF) relative to the reference 
structure for the backbone atoms of human α-thrombin bound to natural TBA and the modified 
aptamers TBA-G3EIF-Ac and TBA-G3FIE-Ac. The curves represent the average value of RMSF 
obtained from 8 MD simulations, considering the last 10 ns of production run. The main 











Supplementary Table 1. Binding free energy calculated by MM-GBSA methodology and its 
components of α-thrombin/TBA, α-thrombin/TBA-G3FIE-Ac and α-thrombin/TBA-G3EIF-Ac 
complexes obtained in eight replicates. Data are provided in kcal mol-1. 
Systems Replicates ΔEvdw ΔEELE ΔEGB ΔEsurf ΔG polb ΔG nonpolc ΔGbindd TΔS ΔG(ΔΔG)e 
TBA rep1 -59.6 -1409.50 1414.8 -6.5 5.3 -66.1 -60.8 -40.3 -20.5 
rep2 -81.1 -1454.9 1475.4 -9.5 20.4 -90.6 -70.2 -40.03 -30.1 
rep3 -45.0 -1484.2 1483.5 -4.8 -0.7 -49.8 -50.5 -35.8 -14.7 
rep4 -60.8 -1363.9 1376.7 -6.6 12.8 -67.4 -54.5 -36.9 -17.6 
rep5 -59.9 -1437.9 1435.0 -6.1 -2.9 -66.0 -68.9 -27.9 -40.9 
  rep6 -63.5 -1389.1 1394.2 -7.0 5.2 -70.5 -65.3 -38.7 -26.6 
  rep7 -61.8 -1351.1 1351.8 -7.0 0.7 -68.8 -68.1 -36.6 -31.5 
  rep8 -68.4 -1516.0 1518.4 -7.5 2.4 -75.9 -73.5 -46.6 -26.8 
 Average ± 
SEM 
-62.5±4.1 -1425.8±23.7 1431.2±23.5 -6.9±0.5 5.4±3.2 -69.4±4.6 -64.0±3.3 -37.9±2.1 -26.1±3.9 
 TBA-G3FIE-
Ac 
rep1 -63.5 -1608.5 1608.8 -6.9 0.3 -70.4 -70.1 -42.4 -27.7 
  rep2 -39.5 -1477.4 1483.3 -4.7 5.9 -44.3 -38.4 -31.3 -7.1 
 rep3 -76.1 -1596.1 1615.9 -9.1 19.9 -85.3 -65.4 -36.7 -28.7 
  rep4 -35.8 -1521.6 1519.6 -4.2 -2.0 -40.0 -42.0 -29.5 -12.5 
  rep5 -68.5 -1500.1 1526.4 -8.4 26.3 -76.9 -51.0 -47.0 -3.6 
  rep6 -58.9 -1518.8 1528.1 -7.9 9.3 -66.7 -57.5 -33.2 -24.3 
  rep7 -64.1 -1709.5 1714.2 -8.0 4.8 -72.1 -67.3 -38.4 -28.9 
  rep8 -69.0 -1742.6 1747.7 -8.8 5.1 -77.8 -72.7 -38.6 -34.1 
  Average ± 
SEM 
-59.4±5.9 -1584.3±40.3 1593.0±39.5 -7.2±0.8 8.7±4.0 -66.7±6.6 -58.0±5.4 -37.1 ± 2.4 -20.8±5.9 
 TBA-G3EIF-
Ac 
rep1 -47.4 -1658.1 1649.3 -5.7 -8.8 -53.1 -61.8 -32.8 -29.0 
  rep2 -92.2 -1712.3 1717.9 -11.3 5.6 -103.6 -97.9 -42.7 -55.3 
 rep3 -85.3 -1649.1 1663.8 -10.5 14.7 -95.7 -81.0 -45.9 -35.1 
  rep4 -81.0 -1625.4 1634.4 -9.7 9.1 -90.7 -81.6 -46.0 -35.6 
  rep5 -73.3 -1829.3 1810.8 -9.7 -18.5 -83.1 -101.6 -42.8 -58.8 
  rep6 -95.6 -1870.2 1867.9 -11.5 -2.4 -107.2 -109.5 -62.9 -46.6 
  rep7 -102.3 -1726.8 1736.5 -11.9 9.7 -114.2 -104.5 -38.4 -66.1 
  rep8 -69.31 -1778.94 1786.85 -7.60 7.91 -76.91 -68.99 -42.2 -26.8 
  Average ± 
SEM -80.8±7.1 -1731.3±36.2 1733.4±34.1 -9.7±0.9 2.2±4.6 -90.5±8.0 -88.4±7.2 -44.2±3.5 -44.1±8.0 
 The symbols depicted in the table columns corresponds to: ΔEVDW, van der Waals energy; ΔEELE, electrostatic energy; ΔEGB, 
electrostatic contribution to the solvation free energy calculated by GB; ΔGSA, non-polar contribution to the solvation free energy 
calculated with LCPO method; b ΔGpol = ΔEELE + ΔGGB; c ΔGnonpol = ΔEVDW + ΔGSA; d ΔGbind = ΔEELE + ΔEGB + ΔEVDW + ΔGSA; TΔS, 
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